Micropillar-based phenotypic screening platform uncovers involvement of HDAC2 in nuclear deformability

Biomaterials. 2022 Jul:286:121564. doi: 10.1016/j.biomaterials.2022.121564. Epub 2022 May 6.

Abstract

Nuclear deformation is an essential phenomenon allowing cell migration and can be observed in association with pathological conditions such as laminopathies, neurodegenerative disorders and diabetes. Abnormal nuclear morphologies are a hallmark of cancer progression and nuclear deformability is a necessary feature for metastatic progression. Nevertheless, the cellular processes and the key molecular components controlling nuclear shape are poorly understood, in part due to a limited availability of assays that allow high-throughput screening of nuclear morphology-phenotypes. In this study, we explore the application of micropillared substrates as the basis for a phenotypic screening platform aimed at identifying novel determinants of nuclear morphology. We designed PDMS substrates to maximize simplicity in image acquisition and analyses, and in a small-scale screening of inhibitors targeting chromatin-modifying enzymes, we identify histone deacetylation as cellular process involved in nuclear deformation. With increasingly specific targeting approaches, we identify HDAC2 as a novel player in controlling nuclear morphology through gene transcription repression. This study shows the effectiveness of micropillar-based substrates to act as phenotypic drug screening platforms and opens a new avenue in the identification of genes involved in determining the nuclear shape.

Keywords: HDAC inhibitor; HDAC2; Micropillar; Nuclear deformability; Nuclear shape.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatin / genetics
  • Chromatin / metabolism
  • Drug Evaluation, Preclinical
  • Histone Deacetylase 2* / genetics
  • Histone Deacetylase 2* / metabolism
  • Humans
  • Neoplasms*
  • Phenotype

Substances

  • Chromatin
  • HDAC2 protein, human
  • Histone Deacetylase 2